Shih-Shih Chen

My lab focuses on the tumor microenvironment as a risk factor for chronic lymphocytic leukemia (CLL) and Richter's transformation (RT). We develop therapeutic strategies targeting the interaction between CLL/RT and the TME. This research has been my focus since my postdoctoral studies, where I investigated auto-antigens in the TCL-1 mouse model and expanded this work in TCL-1/IgK-AID double transgenic mice that develop RT spontaneously. I've also created preclinical CLL patient-derived xenograft (PDX) models, including SRG-BA6 mice, which allow for the study of human lymph node fibroblastic stromal cells. Recently, I’ve gained expertise in single nucleus RNA sequencing, multiplex imaging, and using PDX models to develop novel therapies like R110-CART for CLL and RT. My lab is committed to interdisciplinary studies with therapeutic implications, and I have extensive experience in project management and collaboration, positioning me well to advance this research.